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Accumulation of multiple 
neurodegenerative disease-related 
proteins in familial frontotemporal 
lobar degeneration associated with 
granulin mutation
Masato Hosokawa  1, Hiromi Kondo2, Geidy E. Serrano3, Thomas G. Beach3, Andrew C. 
Robinson4, David M. Mann4, Haruhiko Akiyama1, Masato Hasegawa1 & Tetsuaki Arai1,5
In 2006, mutations in the granulin gene were identified in patients with familial Frontotemporal Lobar 
Degeneration. Granulin transcript haploinsufficiency has been proposed as a disease mechanism that 
leads to the loss of functional progranulin protein. Granulin mutations were initially found in tau-
negative patients, though recent findings indicate that these mutations are associated with other 
neurodegenerative disorders with tau pathology, including Alzheimer’s disease and corticobasal 
degeneration. Moreover, a reduction in progranulin in tau transgenic mice is associated with increasing 
tau accumulation. To investigate the influence of a decline in progranulin protein on other forms of 
neurodegenerative-related protein accumulation, human granulin mutation cases were investigated 
by histochemical and biochemical analyses. Results showed a neuronal and glial tau accumulation in 
granulin mutation cases. Tau staining revealed neuronal pretangle forms and glial tau in both astrocytes 
and oligodendrocytes. Furthermore, phosphorylated α-synuclein-positive structures were also found 
in oligodendrocytes and the neuropil. Immunoblot analysis of fresh frozen brain tissues revealed that 
tau was present in the sarkosyl-insoluble fraction, and composed of three- and four-repeat tau isoforms, 
resembling Alzheimer’s disease. Our data suggest that progranulin reduction might be the cause of 
multiple proteinopathies due to the accelerating accumulation of abnormal proteins including TDP-43 
proteinopathy, tauopathy and α-synucleinopathy.
Progranulin (PGRN) is a growth factor encoded by a single gene on chromosome 17q21, extremely close to the 
MAPT (tau) gene. PGRN is a 593 amino acid, cysteine-rich protein with a signal peptide and 7.5 highly conserved 
tandem granulin repeats of a 12-cysteinyl motif. It is involved in the regulation of multiple processes, including 
neuronal inflammation1, wound healing2, 3, cell growth4, 5, tumorigenesis6 and chemoattraction of microglia7. 
Granulin (GRN) null mutations were identified in familial frontotemporal dementia (FTD) linked to chromo-
some 17q21 with tau-negative, ubiquitin-positive inclusions8, 9. Many mutations including those due to a frame 
shift by insertion/deletion or substitution of a nucleotide have been reported, and been shown to generate pre-
mature termination codons. GRN transcript haploinsufficiency has been proposed as the disease mechanism 
that leads to the loss of functional PGRN protein. A mutation in the signal peptide may cause mislocalization of 
PGRN in a protein secretion pathway or induce loss of PGRN function by impairment of its transport10, 11. Thus, 
these mutations are strongly involved in FTD pathogenesis.
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Interestingly, loss-of-function GRN mutations have been identified in patients clinically diagnosed with 
Alzheimer’s disease (AD)12–19. For example, p.Gly35Arg (c.103G > A)19, and a single base pair deletion (c. 
154delA) were found in AD, and the latter was shown to cause a frame shift (p.Thr52HisfsX2) creating a pre-
mature stop codon20. The rs5848 (3′ UTR + 78C > T) variant was also found in AD21 and associated with an 
increased risk of this disease22. In addition, GRN mutations were found in the accelerating accumulation of 
abnormal proteins in corticobasal syndrome10, 23–26. Furthermore, tau pathology, in addition to TAR-DNA bind-
ing protein of 43 kDa (TDP-43) pathology, was found in most members of two families harboring a GRN muta-
tion27. These findings suggest that a decline in, or dysfunction of, PGRN may cause tau abnormalities, leading 
to the formation of tau pathology by activation of cyclin-dependent kinases in a P301L tau/GRN +/− mouse 
model28. To explore these issues, we performed immunohistochemical staining and biochemical analyses on 
human familial GRN mutation cases and examined whether GRN reduction accelerates the accumulation of 
neurodegenerative-related proteins other than TDP-43.
In this study, using a novel, highly sensitive immunohistochemical method employing free-floating sec-
tions, we noted massive phosphorylated-tau-positive staining in some familial GRN mutation cases. Notably, 
in these same cases, we also observed significant phosphorylated α-synuclein positive staining. Additionally, 
detergent-insoluble tau and α-synuclein proteins were detected by immunoblot analysis. Similar tau pathol-
ogy was not seen in other GRN mutation cases when employing standard immunohistochemistry based on 
paraffin-embedded sections. Our results suggest that at least some cases with GRN mutations may show a hitherto 
unrecognized accelerated pathological accumulation of tau and α-synuclein.
Materials and Methods
Ethics Statement. All patients, or in some cases in which the patient had died, next of kin, provided written 
consent for autopsy and postmortem analyses for research purposes. Written informed consent was obtained 
from all patients. This study was approved by the Ethics Committee of the Tokyo Metropolitan Institute of 
Medical Science (permission No. 15-1 and 15-5(1)), the Banner Sun Health Research Institute and University of 
Manchester. The study was performed in accordance with the ethical standards laid down in the 1964 declaration 
of Helsinki and its later amendments.
Cases. The brain tissues used in Study A from four patients with GRN and three controls were from the 
Banner Sun Health Research Institute (Sun City, AZ), Brain and Body Donation Program29, 30. The additional 
nine GRN mutation cases in Study B were from the Manchester Brain Bank (UK). Ten control cases in Study B 
were registered in the autopsy archives of Dementia Research Project, Tokyo Metropolitan Institute of Medical 
Science. Case details are presented in Table 1. Seven different GRN mutations were recorded. Briefly, Case 1 
had a c.1252C > T mutation resulting in p.Arg418X. Cases 2, 4, 9 and 12 had a c.1477C > T mutation resulting 
in p.Arg493X. A point mutation in a translation initiation codon (c.1A > C) predicted reduced mRNA levels 
in case 3. Three patients (cases 8, 14 and 16) shared c.1355delG mutation resulting in p.V452WfsX38. Case 10 
had a c.1402C > T mutation resulting in p.Q468X and case 13 had a c.90_91insCTGC mutation resulting in 
p.C31LfsX34. Two patients (cases 11 and 15) shared c.388_391delCAGT mutation resulting in p.Q130SfsX124.
Histochemical analysis. Study A: For immunohistochemistry, sections fixed in 4% paraformaldehyde and 
preserved in 20% sucrose were cut serially on a freezing microtome at 40 μm thickness, collected in maintenance 
solution, and immunostained as free-floating sections (cases 1–7). Sections were incubated with 1% H2O2 for 
30 min to eliminate endogenous peroxidase activity and were pretreated by autoclaving for 10 min in 10 mM 
sodium citrate buffer, pH6.0, at 121 °C. Sections were incubated for 24 hours with AT8 (1:1,000, Innogenetics, 
Ghent, Belgium), anti-TDP-43-pS409/410 antibody (1:1,000, Dr. Hasegawa), anti-phosphorylated α-synuclein 
antibody (1175, 1:1,000, Dr. Akiyama), E50 (for amyloid β, 1:10,000, Dr. Akiyama), RD3 (1:1,000, Merck 
Millipore), anti-4R tau (1:1,000, Dr. Hasegawa) or anti-FUS (1:1000, Sigma-Aldrich, St. Louis, MO, USA).
Study B: As we could not obtain sections in cases 8–26 that had been fixed and preserved under the same 
conditions as cases 1–7, we used formalin-fixed, paraffin-embedded sections instead. Therefore, sections 
from cases 8–26 were cut at 10 μm thickness, deparaffinized, incubated with 1% H2O2 for 30 min to elimi-
nate endogenous peroxidase activity in the tissue, then pretreated for 10 min in 10 mM sodium citrate buffer, 
pH6.0 at 110 °C. Sections were then treated with formic acid for 10 min (for α-synuclein staining) or 30 min 
(for tau staining). For tau immunostaining, sections were incubated in 10 μg/ml of trypsin (Sigma-Aldrich) at 
37 °C for 10 min. They were also incubated with AT8 and anti-phosphorylated α-synuclein antibody (1175), 
overnight, as in Study A. Antibody labeling was performed by incubation with goat anti-rabbit IgG (1:1,000, 
Vector Laboratories, Burlingame, CA, USA) or horse anti-mouse IgG (1:1,000, Vector Laboratories) for 3 hours. 
The antibody labeling was visualized by incubation with avidin-biotinylated horseradish peroxidase complex 
(ABC Elite, Vector Laboratories, 1:1,000) for 3 hours, followed by incubation with a solution containing 0.01% 
3,3′-diaminobenzidine, 1% nickel ammonium sulfate, 0.05 M imidazole and 0.00015% H2O2 in 0.05 M Tris-HCl 
buffer, pH 7.6. Counter nuclear staining was performed with Kernechtrot stain solution (Merck, Darmstadt, 
Germany) or hematoxylin (Muto Pure Chemicals, Tokyo, Japan). The sections were then rinsed with distilled 
water, mounted on glass slides, treated with xylene, and coverslipped with Entellan (Merck). Tissue sections 
(cases 1–4) were also stained using a modified Gallyas-Braak method. Photographs were taken with a BX53 
microscope (Olympus, Tokyo, Japan).
For fluorescent immunohistochemistry, free floating sections were incubated for 10 min with 0.1% Sudan 
black/70% ethanol solution and then incubated for 24 hours with AT8 (1:500), anti-TDP-43-pS409/410 anti-
body (1:500), anti-phosphorylated α-synuclein antibody (1175, 1:500) or pSyn#64 (1:500, Wako, Osaka, Japan). 
Antibody labeling was visualized by incubation with Alexa 488- or 568-labeled anti-rabbit IgG (1:100, Invitrogen, 
Carlsbad, CA, USA) or Alexa 488- or 568-labeled anti-mouse IgG (1:100, Invitrogen) for 2 hours. The sections 
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were coverslipped with ProLong Gold with 4′,6-diamidino-2-phenylindole (Invitrogen). Photographs were taken 
with a BZ-8000 (Keyence, Osaka, Japan).
Sequential fractionation of brain extracts. Frozen brain samples (middle frontal gyrus, approximately, 
0.2 g) were homogenized in 10 volumes of A68 buffer (10 mM Tris-HCl, pH 7.5, 0.8 M NaCl, 1 mM ethylene glycol 
bis-N, N, N′, N′-tetraacetic acid, 10% sucrose) containing 1% sarkosyl followed by incubation for 30 min at 37 °C. 
Each brain homogenate was centrifuged at 15,000 rpm for 10 min at 4 °C, and the supernatant was collected. The 
supernatant was then centrifuged at 136,000× g for 20 min at 4 °C. The sarkosyl-insoluble pellet was sonicated in 
60 μl of SDS-PAGE sample buffer containing 4 M urea.
Histopathological assessments. Age-related plaque scores were determined using the Braak staging31. 
For purpose of this protocol, the letter corresponds to the following assessment: 0 = No Aβ deposits, A = initial 
Aβ deposits can be found in basal portions of the isocortex, B = Aβ deposits can be shown in virtually all isocor-
tical association areas, C = Aβ deposits can be seen in all areas of the isocortex, including the sensory and motor 
core fields. For the evaluation of neurofibrillary changes (tau deposition), Braak staging was applied31. In this pro-
tocol, the number corresponds to the following assessment of the area of tau deposition: Stage I = transentorhi-
nal cortex, Stage II = entorhinal cortex, Stage III = hippocampus-subiculum, Stage IV = temporal cortex, Stage 
V = parietal cortex, and Stage VI = occipital cortex. The degree of accumulation of tau and α-synuclein was also 
evaluated qualitatively and a score ranging from – (negative) to +++ (severe) was assigned.
Immunoblotting analyses. For immunoblotting, brain extracts from the GRN mutation cases were 
boiled for 5 minutes with SDS-PAGE sample buffer (60 mM Tris-HCl, pH 6.8, containing 2% SDS, 10% glyc-
erol, 0.025% bromophenol blue and 5% mercaptoethanol) and loaded onto a 5–20% acrylamide minigel. Loaded 
samples were electrophoresed for 75 minutes at 200 V with molecular weight markers (Bio-Rad, Hercules, CA, 
Case 
No. Gender
Age at 
death Clinical diagnosis
Pathological 
diagnosis Mutation (cDNA) Mutation (Protein) APOE
Tau 
haplotype
Brain 
weight (g)
1 M 54 AD/PiD FTLD-TDP Type A/HS c.1252C > T p.R418X n.d. H1/H2 980
2 F 56 FTD/AD FTLD-TDP Type A/LBD c.1477C > T p.R493X n.d. n.d. 940
3 F 72 AD FTLD-TDP Type A/AD c.1A > C p.0 n.d. H1/H1 1120
4 M 55 AD FTLD-TDP Type A/HS/LBD c.1477C > T p.R493X n.d. H1/H1 800
5 M 73 Myeloid leukemia
Age changes only None None
n.d. n.d. 1240
6 M 76 Multiple myeloma n.d. n.d. 1375
7 M 79 Prostate cancer n.d. n.d. 1428
8 F 71 FTD
FTLD-TDP 
Type A
c.1355delG p.V452WfsX38 E3/E3 H2/H2 955
9 F 61 FTD c.1477C > T p.R493X n.d. n.d. 900
10 F 66 FTD c.1402C > T p.Q468X E3/E3 H1/H1 1100
11 F 71 PNFA c.388_391delCAGT p.Q130Sfs124 E3/E3 H1/H1 863
12 M 66 FTD c.1477C > T p.R493X E3/E3 H2/H2 1495
13 M 73 Prog Anomia c.90_91insCTGC p.C31LfsX34 E3/E3 n.d. 1250
14 M 71 CBD/PAX c.1355delG p.V452WfsX38 E3/E4 H2/H2 925
15 M 73 PiD c.388_391delCAGT p.Q130Sfs124 E3/E3 n.d. 980
16 M 72 PNFA c.1355delG p.V452WfsX38 E3/E4 H1/H2 870
17 M 66 Narcolepsy
Age changes only None None
n.d. n.d. 1221
18 F 63 Spinal muscular atrophy n.d. n.d. 1221
19 M 51 Sch n.d. n.d. 1332
20 M 50 Candidal meningitis n.d. n.d. 1300
21 F 53 Atypical psychosis n.d. n.d. ?
22 M 63 Sch/Parkinson’s syndrome n.d. n.d. ?
23 M 51 Sch/Aspiration pneumonia n.d. n.d. 1494
24 M 60 Sch/Aspiration pneumonia n.d. n.d. 1435
25 M 63 Sch/Pseudomonas aeruginosa pneumonia n.d. n.d. 1430
26 M 57 Sch/Multiple myeloma n.d. n.d. 1149
Table 1. Description of the GRN mutation and control cases used in the initial study (Study A, No. 1–7) and the 
additional cases used in the second study (Study B, No. 8–26). n.d.: not determined, Gender: F, female; M, Male. 
AD, Alzheimer’s disease; CBD, corticobasal degeneration; FTD, frontotemporal dementia; HS, hippocampal 
sclerosis; LBD, Lewy body disease; PAX, apraxia; PiD, Pick’s disease; PNFA, progressive non-fluent aphasia; 
Prog Anomia, progressive anomia; Sch, schizophrenia.
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USA). Electrophoresed proteins were transferred onto a polyvinylidene difluoride membrane (Merck Millipore) 
and subjected to 200 mA for 60 minutes. The printed membranes were blocked with 3% gelatin for 15 min and 
then incubated in a primary antibody solution, T46, (1:1,000, Innogenetics), RD3 (1:1,000, Merck Millipore), 
anti-4R tau (1:1,000, Dr. Hasegawa) for overnight at room temperature. Following incubation with the secondary 
anti-mouse or anti-rabbit antibody (1:50,000, Bio-Rad), immunoreactivity was detected by the chemilumines-
cence method using a Super Signal West Dura Extended Duration Substrate (Thermo Fisher Scientific, West Palm 
Beach, FL, USA) and was visualized with a LAS-4000 mini (GE Healthcare UK Ltd., Buckinghamshire, UK). 
For α-synuclein immunoblot, the printed membranes were incubated in a primary antibody solution, 
anti-phosphorylated α-synuclein antibody (1175, 1:1,000) or pSyn#64 (1:1,000) for overnight at room temper-
ature. Following incubation with the biotinylated-secondary anti-rabbit or anti-mouse antibody (1:500, Vector 
Laboratories), followed by Vectastain Elite ABC kit (Vector Laboratories). Immunoreactivity was detected by 
3,3′-diaminobenzidine with nickel chloride.
Results
GRN mutation cases used in the present study. The age, gender, clinical and pathological diagnoses 
and genetic information on the familial GRN mutation cases and control cases used in this study is summarized 
in Table 1. None of the GRN mutation cases examined in this study had MAPT mutation, and the MAPT haplo-
type was determined to be H1/H1 in cases 3, 4, 10 and 11, H1/H2 in cases 1 and 16, H2/H2 in cases 8, 12 and 14 
(Table 1). The MAPT haplotype of cases 2, 9, 13 and 15 were unknown.
TDP-43 accumulation in GRN mutation cases. Phosphorylated TDP-43 inclusions were visualized by 
anti-TDP-43-pS409/410 antibody. Neuronal cytoplasmic inclusions (NCIs) and dystrophic neurites (DNs) were 
observed in the cerebral cortices of GRN mutation cases 1–4 (Fig. 1A–D) and cases 8–16 (data not shown). All 
thirteen GRN mutation cases were categorized as “Type A” according to the classification system of Mackenzie et 
al.32, consistent with that type of TDP-43 pathology previously reported in GRN mutation cases (Tables 2 and 3). 
All control cases (5–7 and 17–26) were negative for phosphorylated TDP-43 (Tables 2 and 3).
Tau accumulation in GRN mutation cases. We observed a considerable number of tau-positive neurons, 
astrocytes and oligodendrocytes in all 4 Study A GRN mutation cases by either AT8 immunostaining (Fig. 2, and 
Table 2) or Gallyas silver staining (data not shown). In particular, case 2 showed massive AT8-positive struc-
tures in the entorhinal cortex, hippocampus (Fig. 2A), amygdala (Fig. 2B), temporal cortex (Fig. 2C), insula. In 
the temporal lobe, the majority of tau-positive neuronal cytoplasmic staining appeared as pretangle-like forms 
(Fig. 2A,F,G,H). In the neuropil, fine tau–positive granules were abundant (Fig. 2C). The size of most of these 
Figure 1. Immunohistochemical staining of the temporal lobe of GRN mutation cases with antibody to 
phosphorylated TDP-43. Numerous neuronal cytoplasmic inclusions (arrows) and dystrophic neurites 
(arrowheads) were stained with anti-TDP-43-pS409/410 antibody in cases 1 (A), 2 (B), 3 (C) and 4 (D). The 
sections were counterstained with hematoxylin. The scale bar in (A) applies to all photomicrographs (100 μm).
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granules appeared smaller than the tau-positive grains observed in argyrophilic grain disease (AGD) brains, and 
they were negative for Gallyas-silver staining (data not shown).
Furthermore, tau-positive astrocytic structures, resembling “bush-like” astrocytes previously reported in 
AGD33, were found in the cortex in all cases in Study A. Their morphology was significantly different from the 
tufted-astrocytes in progressive non-fluent aphasia (PSP) patients, the astrocytic plaques in corticobasal degener-
ation (CBD) or the ramified astrocytes in Pick’s disease (Fig. 2D). In the white matter, tau-positive oligodendro-
glial coiled bodies were observed (Fig. 2E).
Gallyas silver staining also revealed structures similar to those stained with AT8, including neurofibrillary 
tangles (NFTs), threads, and astrocytic and oligodendrocytic structures (data not shown). In the hippocampal 
region, many NFTs were found in cases 2 and 4 by both AT8 immunostaining and Gallyas silver staining (data not 
shown). The control cases of Study A showed mild to moderate AT8-positive structures and less glial tau deposi-
tion compared to GRN mutation cases (Table 2). Case 1, 2, 4 and 5 exhibited tau deposition that corresponded to 
Braak stage IV, Case 3 corresponded to Braak stage V and Case 6 and 7 corresponded to Braak stage I, respectively 
(Table 2). The degree of accumulation of tau was evaluated qualitatively and a score ranging from – (negative) to 
+++ (severe) was assigned (Supplementary Figure 1 and Table 2).
In Study B, eight of nine GRN mutation cases exhibited some AT8 immunoreactivity (Supplementary Figure 2 
and Table 3), but the levels of phosphorylated tau deposition were up to Braak stage II except for Case 9 (Table 3), 
dissimilar to that seen in GRN mutation cases of Study A. No tau deposition or only Braak stage I-II were 
observed in the control cases of study B (Table 3). The tau pathology in the GRN mutation cases (Study A) was 
also detected by 3-repeat (3R)-tau (RD3) and 4-repeat (4R)-tau (anti-4R) specific antibodies indicating that both 
3R and 4R tau accumulation was present (Data not shown).
α-synuclein accumulation in GRN mutation cases. Immunohistochemistry using an antibody to 
phosphorylated α-synuclein, revealed small round or dot-like structures and short thread-like structures in the 
Case 
No. Case Age TDP-43 Aβ Tau
Tau (neuronal/glial) α-syn
Hip-Ent Amygdala Temporal Frontal Hip-Ent Amygdala Temporal
1
GRN mutation
54
FTLD-TDP 
(Type A)
A IV +++/+ ++/+ +/+ +/+ ++ + +
2 56 0 IV +++/++ +++/++ +++/++ ++/++ + N.A. +
3 72 C V +++/+ ++/+ +++/++ +++/- N.A. + +
4 55 A IV +++/+ +/+ +/+ +/+ +++ + ++
5
Control
73
Negative
B IV ++/− ++/+ ++/+ N.A. + + −
6 76 A I +/− +/− +/− N.A. + + −
7 79 A I ++/− +/+ +/+ N.A. + + −
Table 2. Summary of immunohistochemical analyses of the initial study (Study A, No. 1–7). +mild, 
++moderate, +++severe, −negative, N.A.: not available.
Case 
No. Case Age TDP-43 Aβ Tau α-syn
8
GRN mutation
71
FTLD-
TDP 
(Type A)
A I
Negative
9 61 0 IV
10 66 0 II
11 71 0 II
12 66 0 I
13 73 0 II
14 71 B I
15 73 0 0
16 72 A II
17
Control
66
Negative
0 II
18 63 0 0
19 51 0 I
20 50 A 0
21 53 0 I
22 63 0 I
23 51 0 0
24 60 A I
25 63 0 0
26 57 0 0
Table 3. Summary of immunohistochemical analyses of the second study (Study B, No. 8–26).
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temporal lobe (Fig. 3A–F), and oligodendroglial coiled body-like structures in the temporal white matter (data 
not shown) in cases 1–4 of Study A. The degree of accumulation of α-synuclein was evaluated qualitatively and a 
score ranging from – (negative) to +++ (severe) was assigned. In particular, case 4 exhibited atypical α-synuclein 
Figure 2. Photomicrograph of phosphorylated tau immunohistochemistry of the temporal lobe of the GRN 
mutation cases. Massive AT8-positive structures were observed in the hippocampus (A), amygdala (B), inferior 
temporal cortex (C) in case 2. AT8-positive astrocytes were observed in the temporal cortex (D) and AT8-
positive oligodendrocytes in the white matter of temporal lobe (E) in case 2. AT8-positive deposition was also 
detected in amygdala in case 1 (F), hippocampus in case 3 (G) and entorhinal cortex in case 4 (H). The sections 
were counterstained with Kernechtrot stain solution. The scale bar in A applies to (B,C,D,F,G and H) (200 μm), 
in E (100 μm), respectively. The scale bars in the inserts are 50 μm (C and D) and 25 μm (E), respectively.
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deposition in the temporal cortex (Fig. 3A,B and Table 2). Phosphorylated α-synuclein positive structures were 
not found in Study B using paraffin-embedded sections of GRN mutation cases (cases 8–16, Table 3) and control 
cases (cases 17–26, Table 3).
Amyloid β deposition in GRN mutation cases. Aβ deposition was found in the temporal lobe in three 
of four GRN mutation cases in Study A (Fig. 4 and Table 2). In the cases 1 and 4, Aβ pathology was present mostly 
as diffuse plaques, corresponding to Braak stage A (Fig. 4A and D). In case 2, there was no Aβ pathology (Fig. 4B) 
but case 3 corresponded with Braak stage C (Fig. 4C). Of the control cases in Study A, three were similar to Braak 
stage A, but one (case 5) corresponded to Braak stage B. In Study B, Aβ accumulation in almost all cases corre-
sponded to Braak stage 0, the others showing Braak stage A (Table 3).
Immunoblot analyses. Biochemical features of accumulated tau in cases of GRN mutation (Fig. 5, Case 
3: lane 1, Case 4: lane 2) were compared with those of other tauopathies including CBD (lane 3), PSP (lane 4) 
and AD (lane 5) by immunoblot analysis of the sarkosyl-insoluble fraction using C-terminal tau antibody (T46) 
(Fig. 5). The major tau band pattern in GRN mutation cases was triplets of 68, 64 and 60 kDa, similar to that in 
AD, but different from that in CBD and PSP (Fig. 5). GRN mutation cases were also detected by 3R-tau (RD3) 
and 4R-tau (anti-4R) specific antibodies indicating both 3R and 4R tau accumulation (Supplementary Figure 3). 
GRN mutation cases were also studied with anti-phosphorylated α-synuclein antibodies (1175 and pSyn#64) for 
cases 1–4. Very faint bands of phosphorylated α-synuclein were observed at 16 kDa. (Supplementary Figure 4).
Fluorescence immunohistochemistry. Fluorescent double-staining of the temporal lobe of the GRN 
mutation case 4 was performed to examine whether TDP-43/tau (Fig. 6A), TDP-43/α-synuclein (Fig. 6B) or 
tau/α-synuclein (Fig. 6C) were co-localized in the abnormal structures. Colocalization of these proteins was very 
infrequent in most abnormal structures.
Discussion
The results of the present study show that GRN mutations causing PGRN reduction may accelerate the intracel-
lular accumulation of not only TDP-43 but also tau and α-synuclein in the brains of familial FTD patients with 
GRN mutations. This suggests that GRN mutations causing PGRN reduction may be causative or represent risk 
factors for multiple proteinopathies (TDP-43 proteinopathy, tauopathy or α-synucleinopathy).
Immunohistochemical analyses of phosphorylated TDP-43 revealed a considerable number of neuronal cyto-
plasmic inclusions and dystrophic neurites in all GRN mutation cases (Fig. 1, Tables 2 and 3). In FTLD-TDP, 
TDP-43 pathology falls within four histological subtypes (types A-D) based on the predominant type of TDP-
43-positive structures exhibited32. Type A is characterized by numerous short dystrophic neurites and crescentic 
or oval neuronal cytoplasmic inclusions. Cases of FTLD-TDP with a GRN mutation invariably display type A 
pathology34–36, and present observations were in accordance with this.
The very high sensitivity staining method that we performed for Study A (cases 1–7) revealed Case 2 to show 
atypical tauopathy with massive tau deposition in neuron, astrocytes and oligodendrocytes without Aβ deposi-
tion. Case 4 was atypical synucleinopathy with diffuse α-synuclein positive structures that were observed mainly 
in the neocortex. Case 3 exhibited massive Aβ deposition corresponding to Braak Stage C and tau deposition 
Figure 3. Immunohistochemical staining of phosphorylated α-synuclein in the temporal lobe of the GRN 
mutation cases. Phosphorylated α-synuclein -positive structures were observed in the inferior temporal cortex 
(A), superior temporal cortex (B) and tuberomammillary nucleus (C) in case 4, and in the temporal cortex in 
case 1 (D), case 2 (E) and case 3 (F). Sections were counterstained with Kernechtrot stain solution. The scale bar 
in (A) applies to (C–F) (200 μm). The scale bars in (B), in insert (A,C and D–F) are 50 μm.
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corresponding to Braak stage V in AD pathology. Case 1 exhibited tau deposition that corresponded to Braak 
stage IV. It is possible that case 3 might be an incidental complication of AD because the age was late 70 s’. The 
pathology in the other two cases (case 2 and 4), however, is very rarely observed in the normal aging brain at mid-
50 years of age. The control cases in Study A also had levels of tau deposition that corresponded to Braak stage I 
to IV (Table 2), but the average age was higher than that of the GRN mutation cases. We compared abnormal tau 
deposition using the paraffin-embedded tissues of GRN mutation and control cases, and there were significantly 
differences (Study B, Table 3). Though Study B was less obvious differences than Study A. Braak et al. reported 
that for Braak NFT stage III-IV, the ratio was less than 10% at ages 50 s’ to 60 s’37, so that our GRN mutation cases 
in Study A showed tau accumulation atypical for normal aging.
It has been widely accepted for the past decade that there is no tau deposition in GRN mutation brains. 
However, using high-sensitivity immunohistochemical staining, we have found that hyper-accumulated tau and 
α-synuclein can occur in younger GRN mutation cases. Part B of the present study, using paraffin-embedded 
tissues, however, showed only mild tau deposition, as has been previously reported8, 9. Hence, GRN mutation 
may accelerate deposition of tau and α-synuclein but the level of abnormal protein deposition seen in rou-
tine paraffin-embedded sections from GRN cases might not be as strong as that seen than in free-floating sec-
tions and therefore go unrecognized. Re-analysis might be necessary in other GRN mutation cases using this 
high-sensitivity immunohistochemical staining method, or immunoblot analyses on frozen brain tissue, in order 
to gain a fuller appreciation of the level of tau pathology present in such cases.
Our previous report made mention of the fact that a GRN mutation in P301L tau transgenic mice affected 
phosphorylated tau deposition28. The results of the present study support our previous observations in mice. 
It has been reported that PGRN deficiency causes lysosomal dysfunction38. We hypothesized that lysosomal 
dysfunction might reduce protein degradation in brain cells allowing aggregation-prone neurodegenerative 
disease-related proteins to deposit more easily.
The features of tau pathology in GRN mutation cases in this study are of predominantly neuronal pretangles, 
abundant fine granules in the neuropil, and astrocytic and oligodendroglial pathology. It is interesting that fine 
tau-positive granules were reported in the striatum of a brain with a GRN c.709-2A > G mutation27. Among 
tauopathies, the tau pathology most similar to our cases might be found in AGD. However, the size of the fine 
granules in our cases seemed smaller than that of the grains in AGD and they were negative for Gallyas-silver 
staining (data not shown). Although the form of tau-positive astrocytes in our cases was similar to the “bush-like” 
astrocytes in AGD, their Gallyas-positive status in contrast to the Gallyas-negative status of the “bush-like” AGD 
astrocytes33. No FUS accumulation was found in any GRN mutation cases in Study A, thus there might be no or 
little relationship between the GRN mutation and FUS deposition (data not shown).
Immunoblot analysis of our cases using C-terminal tau antibody revealed that the banding patterns of the 
full-length tau in the sarkosyl-insoluble fraction appeared to be essentially the same as that seen in AD (Fig. 5). 
Figure 4. Immunohistochemical staining of amyloid β in the temporal lobe of GRN mutation cases. Amyloid β 
(Aβ) was observed in cases 1 (A), 3 (C) and 4 (D), but not in case 2 (B). Most Aβ-positive structures consisted 
of diffuse plaques. The scale bar in (A) applies to all photomicrographs (1.0 mm) and the scale bar in insert A 
applies to insert (B–D) (250 μm).
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The staining using three and four repeat tau specific antibodies revealed that tau in the sarkosyl-insoluble fraction 
consists of both forms of tau (Supplementary Figure 2). These results suggest that accumulated tau in cases of 
GRN mutation cases contains six tau isoforms just as in AD. However, the distribution of fine granular tau and the 
lack of any or only light Aβ accumulation (Fig. 4) is different from AD pathology. Tau isoforms in GRN mutation 
cases were biochemically different from those in CBD and PSP (Fig. 5). Cases of GRN mutation may therefore 
represent a different tauopathy from that of AD, CBD, PSP and AGD.
In addition to neuronal and glial tau accumulation, the present study also revealed α-synuclein-positive struc-
tures, including small round, dot-like or thread-like structures in the cortex and oligodendroglial coiled body-like 
Figure 5. Comparison of the banding patterns of sarkosyl-insoluble tau on immunoblotting between cases 
with a GRN mutation and those with other tauopathies. Immunoblotting analysis was visualized using the 
T46 antibody for detecting tau in the sarkosyl-insoluble fraction from cases 3 (lane 1) and 4 (lane 2) with GRN 
mutations, and a case each of CBD (lane 3), PSP (lane 4) and AD (lane 5). Molecular weight markers are shown 
on the right (kDa).
Figure 6. Immunofluorescent double-staining of accumulated proteins in the temporal lobe in GRN mutation 
case. Phosphorylated TDP-43, α-synuclein and tau immunoreactivity were obserbed in the temporal lobe of 
GRN mutation case 4. pTDP-43 (red)/pTau (green) (A), pTDP-43 (red)/pα-synuclein (green) (B) and pTau 
(red)/pα-synuclein (green) (C).
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structures in the white matter in the GRN mutation cases in Study A (cases 1–4, Fig. 3). Case number 4 showed 
particularly striking phosphorylated α-synuclein pathology. However, the nine paraffinized GRN mutation cases 
showed no α-synuclein-positive structures. This discrepancy might be caused by fixation or preservation meth-
ods. Leverenz and colleagues reported that α-synuclein pathology was observed in two of seven brains with a 
familial GRN mutation. One case showed brainstem α-synuclein pathology while the other was cortical27.
Accumulations of phosphorylated-tau, α-synuclein and TDP-43 were reported in the brains of 
Guam/Kii-amyotrophic lateral sclerosis (ALS)-parkinsonism-dementia complex (PDC) patients39. The triplet 
tau band patterns (68, 64, and 60 kDa) of immunoblot analysis in the sarkosyl-insoluble fraction of GRN muta-
tion cases (Fig. 5) appeared to be essentially the same among cases with the GRN mutation, AD and Guam/Kii 
ALS-PDC. Fine tau-positive granules were also reported in the cerebral white matter of Guam-PDC cases, in 
which the morphology seemed to resemble that of our cases. Hazy astrocytes were observed in Guam-PDC cases, 
but their morphology seemed to differ from that of our cases. To date, no GRN mutations in Guam/Kii ALS-PDC 
cases have been reported. Very recently we reported that the GRN mutation leads lysosomal dysfunction40. We 
speculated that there could be common pathway(s) in lysosomal function or that these diseases have something 
common features of protein aggregation because of the similarities (TDP-43, tau, α-synuclein deposition and 
3R/4R tau isoform aggregation).
In conclusion, when using a highly sensitive free-floating immunohistochemical technique combined with 
western blotting, we have shown widespread pathological tau and α-synuclein deposition in neurons and glial 
cells in familial GRN mutation cases that are not apparent when using standard immunohistochemical methods 
based on routine paraffin embedded sections. Although, the number of samples for this study was small and we 
recognize the limits of this study, our findings suggest that the pathologies seen in GRN mutation cases may pos-
sibly be renamed “neuronoglial multiple proteinopathies”.
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